This review critically synthesizes and evaluates current evidence on the therapeutic potential of natural compounds in MS, with a focus on cross-compound class integration of core common pathways (e.g., NF-κB inhibition and Th17/Treg balance modulation) rather than isolated mechanism descriptions. The gene discussed is NFKB1; the disease is myeloid sarcoma.